NASDAQ:BBI Brickell Biotech (BBI) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free BBI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.77▼$0.9352-Week Range N/AVolume31,300 shsAverage Volume206,730 shsMarket Capitalization$6.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Brickell Biotech alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Brickell Biotech Stock (NASDAQ:BBI)Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. BBI Stock News HeadlinesOctober 19, 2023 | bizjournals.comBrickell hotel sold by royal family member for $55MAugust 27, 2023 | dailymail.co.ukPaul Simon and Edie Brickell's daughter speaks out following parents' arrestApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 25, 2023 | bizjournals.comSeattle Biotech NewsApril 10, 2023 | marketwatch.comNuclear Receptor ROR-Gamma Market Size by 2030March 29, 2023 | travel.usnews.comBrickell City CentreMarch 24, 2023 | bizjournals.comBiotech NewsMarch 18, 2023 | techcrunch.com5 strategies for biotech startups to outlast a market downturnApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 14, 2023 | marketwatch.comNuclear Receptor ROR-Gamma Market Application, Product, Sales and Forecast 2023-2028February 27, 2023 | finance.yahoo.comWhat Sunzen Biotech Berhad's (KLSE:SUNZEN) P/E Is Not Telling YouFebruary 27, 2023 | techcrunch.comBiotech proved a surprisingly bright spot in 2022’s startup correctionFebruary 21, 2023 | msn.comPaul Simon Was 50 When He Married a 26-Year-Old Edie BrickellFebruary 19, 2023 | cnbc.comThis biotech hedge fund has elite clients like Yale’s endowment, Tisch. Here are its top betsFebruary 10, 2023 | benzinga.comBest Biotech Penny StocksJanuary 13, 2023 | markets.businessinsider.comVERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery SystemJanuary 9, 2023 | cbsnews.comUSDA approves vaccine for honeybees, biotech company saysJanuary 4, 2023 | marketwatch.comBioreactors and Fermenters Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2028December 28, 2022 | forbes.comBrickell BiotechDecember 18, 2022 | marketwatch.comNuclear Receptor ROR-Gamma Market : Industry Analysis 2023 To 2028 based on Sales, Revenue, Size and ShareDecember 5, 2022 | nz.finance.yahoo.comAtopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightSeptember 13, 2022 | finance.yahoo.comFresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02September 7, 2022 | finance.yahoo.comBrickell Biotech Announces Corporate Rebranding to Fresh Tracks TherapeuticsAugust 11, 2022 | seekingalpha.comBrickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call TranscriptAugust 2, 2022 | benzinga.comBrickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022July 20, 2022 | finance.yahoo.comBrickell Biotech Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 6, 2022 | finance.yahoo.comBrickell Biotech to Participate at William Blair Biotech Focus Conference 2022See More Headlines Receive BBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2022Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BBI CUSIPN/A CIK819050 Webwww.brickellbio.com Phone(720) 505-4755Fax858-646-1150Employees16Year Founded2009Profitability EPS (Most Recent Fiscal Year)($13.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,470,000.00 Net Margins-643.48% Pretax Margin-643.48% Return on Equity-156.10% Return on Assets-128.23% Debt Debt-to-Equity RatioN/A Current Ratio6.36 Quick Ratio6.36 Sales & Book Value Annual Sales$4.64 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.75 per share Price / BookN/AMiscellaneous Outstanding Shares2,874,000Free Float2,744,000Market Cap$6.75 million OptionableNot Optionable Beta0.02 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Reginald L. Hardy M.B.A. (Age 64)R.Ph., Co-Founder & Chairman Comp: $76.83kAttorney Robert Busard Brown (Age 60)CEO & Director Comp: $816.73kMr. Andrew D. Sklawer (Age 38)Co-Founder, Pres, COO & Sec. Comp: $559.58kMr. Deepak Chadha M.B.A. (Age 52)M.S., MBA, MS, RAC, Chief R&D Officer Comp: $543.59kMr. Albert Nicholas Marchio II (Age 70)CFO and Principal Accounting & Financial Officer Mr. David R. Mcavoy J.D. (Age 59)Gen. Counsel & Chief Compliance Officer Mr. Gary S. Walker (Age 62)Chief Marketing Officer Aron Aizenstat M.B.A.P.M.P., VP of Corp. Devel. & OperationsMs. Sue FattorHead of Human ResourceMs. Nancy SerettaVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsTitan PharmaceuticalsNASDAQ:TTNPCreative Medical TechnologyNASDAQ:CELZChromocell TherapeuticsNYSE:CHROFresh Tracks TherapeuticsNASDAQ:FRTXSorrento TherapeuticsNASDAQ:SRNEView All Competitors BBI Stock Analysis - Frequently Asked Questions How were Brickell Biotech's earnings last quarter? Brickell Biotech, Inc. (NASDAQ:BBI) announced its earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative trailing twelve-month return on equity of 156.10%. During the same period last year, the business earned ($7.21) EPS. When did Brickell Biotech's stock split? Brickell Biotech's stock reverse split on Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Brickell Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO). This page (NASDAQ:BBI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brickell Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
